ADC Biotechnology
Simplifies the conjugation process in the production of new antibody drug conjugate (ADC) based anti-cancer drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| GBP | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (2 %) | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (158 %) | (274 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (171 %) | (337 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ADC BIO is an innovative biotechnology company specializing in the development and production of Antibody Drug Conjugates (ADCs). These are targeted cancer therapies that combine antibodies with cytotoxic drugs to specifically target and kill cancer cells while minimizing damage to healthy cells. ADC BIO serves pharmaceutical companies and biotech firms that are developing the next generation of anticancer drugs. The company operates in the highly specialized and competitive biotechnology market, focusing on process technology to speed up, simplify, and significantly lower the production costs of ADCs.
The business model of ADC BIO revolves around its proprietary Lock Release technology, a fast, simple, cost-efficient, and robust system that ensures ADCs of consistently high quality and purity. This technology is a key differentiator, allowing the company to offer superior products and services to its clients. ADC BIO generates revenue through the development and licensing of its technology, as well as through partnerships and collaborations with pharmaceutical companies.
Keywords: Antibody Drug Conjugates, biotechnology, cancer therapy, Lock Release technology, pharmaceutical, biotech firms, process technology, cost-efficient, high-quality, targeted therapy.